Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer

November 22, 2015

"Research has led to considerable progress in reducing the incidence of breast cancer, as well as mortality rates. Early detection and access to new medications and treatments are tangible proof of these advances. Ten years ago, 82% of women survived five years with the disease, while today the five-year survival rate is 88%. It's a big win," said Nathalie Le Prohon, chair of the Quebec Breast Cancer Foundation. "But there is still much work to do, and this new investment will allow us to continue the fight. We want to thank the public, our donors and our business partners for their generosity, which has helped make this new competition possible. We are very pleased to be able to give back to our community by funding projects that will help Quebec women. We know we will be receiving many high-quality proposals," she added.

It is with enthusiasm that this year, the Cancer Research Society (CRS) has accepted to renew its partnership with the Foundation. "Our contribution will ensure that the research grants will only be awarded to researchers presenting the most deserving and promising projects in breast cancer research in Quebec," states Mario Chevrette, President of the CRS Board of Directors. The Society's long-standing expertise in creating and administering scientific evaluation committees allows for a rigorous evaluation process each year of its funded cancer research projects across Canada.